Chronic Sialorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chronic Sialorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major chronic sialorrhea markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034.

The chronic sialorrhea market has been comprehensively analyzed in IMARC's new report titled "Chronic Sialorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic sialorrhea refers to a nerve and muscle condition that causes an unintentional loss of saliva from the mouth. This disease can contribute to drooling if there's an inability to keep the mouth closed or difficulties swallowing the excess saliva, which can result in excessive spitting. The common symptoms of the ailment include foul odor, dehydration, skin breakdown around the mouth, chapped lips, increased tiredness, etc. Individuals suffering from chronic sialorrhea may also experience infection from skin breakdown, embarrassment, sleep problems, reduced social interactions, irritated skin, etc. Diagnosing this illness typically requires identifying the patient's symptoms, medical history, and clinical screening examinations. The healthcare provider performs neurological workups, including fiberoptic endoscopic evaluation of swallowing (FEES), to support the diagnosis. Additionally, a radiological procedure known as videofluoroscopy, which provides direct, dynamic information on the genesis and aids therapy selection, is further utilized to confirm the prognosis.

The increasing prevalence of neuromuscular or sensory dysfunction, such as cerebral palsy, Parkinson's disease, mental retardation, stroke, etc., which affects the ability to perform the normal compensatory mechanism for excessive salivation, is primarily driving the chronic sialorrhea market. Moreover, the escalating requirement for anticholinergic agents, like glycopyrrolate, tropicamide, benztropine, scopolamine, etc., to treat chronic sialorrhea is further creating a positive outlook for the market. These medications mainly decrease saliva production through the parasympathetic autonomic nervous system by inhibiting salivation and blocking cholinergic muscarinic receptors. Apart from this, the emerging popularity of botulinum toxin injection, owing to its numerous benefits, including limited invasiveness, fewer side effects with greater effectiveness, and improved quality of life in patients, is also bolstering the market growth. Furthermore, the widespread adoption of oral prosthetic devices, such as dental appliances and chin cups, to help with lip closure, tongue positioning, and swallowing is acting as another significant growth-inducing factor. In addition to this, the rising popularity of transoral endoscopic submandibular ganglion neurectomy, since it can provide symptom relief in patients who have failed traditional pharmacological therapies, is expected to drive the chronic sialorrhea market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic sialorrhea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic sialorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic sialorrhea market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic sialorrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic sialorrhea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic sialorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the chronic sialorrhea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic sialorrhea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic sialorrhea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic sialorrhea across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic sialorrhea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic sialorrhea by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic sialorrhea across the seven major markets?
What is the size of the chronic sialorrhea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic sialorrhea?
What will be the growth rate of patients across the seven major markets?

Chronic Sialorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic sialorrhea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic sialorrhea market?
What are the key regulatory events related to the chronic sialorrhea market?
What is the structure of clinical trial landscape by status related to the chronic sialorrhea market?
What is the structure of clinical trial landscape by phase related to the chronic sialorrhea market?
What is the structure of clinical trial landscape by route of administration related to the chronic sialorrhea market?